Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
6
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
6
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
fda
biogen
clinical trials
crispr
eli lilly
ipo
medical devices
medicare
startups
teva pharmaceutical
venture capital
What
new
6
×
bio
roundup
drug
approval
fda
ipo
medicines
remains
activity
advantages
allogene
amgen
approvals
bails
bar
biogen
biogen’s
biopharmaceutical
brand
bridgebio
brings
cancer
candidates
capital
car
clamped
class
companies
convo
covid
crispr
delays
develop
developed
developing
diversity
drugs
earlier
economic
Language
unset
Current search:
novartis
×
new
×
" seattle top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines